Mucin-1 tumor glycoform targeted CAR-NK therapy / CiMaas, Combotope Therap - LARVOL DELTA

Combotope Therapeutics and CiMaas Announce Oncology Research and License Option Agreement (BioSpace) - "Combotope Therapeutics and CiMaas jointly announce an oncology research and license option agreement. Under this agreement, CiMaas has the option to select three tumor glycoform protein targets, with the aim of discovering and developing next-generation CAR-NK and CAR-T antibody-based therapeutics for cancer treatment. The first selected target is the Mucin-1 tumor glycoform. CiMaas will provide funding for the preclinical and clinical development of these candidates up to clinical proof of concept....According to the agreement, CiMaas will provide Combotope Therapeutics with an upfront payment. Combotope Therapeutics will be eligible for potential milestone payments per therapeutic candidate exclusively licensed, developed and commercialized by CiMaas, as well as tiered royalties."

Licensing / partnership • Oncology • Solid Tumor